Q3 2025 Compass Pathways PLC Earnings Call Transcript

Nov 4, 2025 / 01:00 PM GMT

Release Date Price: $6.63 (+11.43%)

Transcript 10-Q8-K

Key Points

Positve

Compass Pathways PLC (CMPS) announced a potential 9 to 12 month acceleration of their launch plans.
The first phase 3 trial, 005, demonstrated a highly statistically significant result for the primary endpoint, de-risking the company.
Enrollment for the second phase 3 trial, 06, has been completed, clarifying the timeline for data disclosures and potential filing.
Positive and collaborative interaction with the FDA supports the acceleration of the planned NDA filing, including the potential for a rolling submission.
The company has maintained a disciplined spending approach, allowing a cash runway into 2027.

Negative

Cash and cash equivalents decreased from $222 million at the end of the second quarter to $186 million at the end of September.
Debt under the Hercules loan facility stands at $31.3 million.
Cash use in operations for the third quarter was $35 million, with expected net cash used in operations for the full year 2025 between $120 and $145 million.
The timing for the R&D tax credit receivable in the UK remains uncertain.
There is no current selection of a specialty partner to support patient access, indicating potential delays in patient support services.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CMPS.OQ - Compass Pathways PLC
Q3 2025 Compass Pathways PLC Earnings Call
Nov 04, 2025 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Compass Pathway's 3rd quarter 2025 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star, followed by the number one on the telephone keypad. If you would like to withdraw your question, please press one again.

Thank you. I would now like to turn the call over to Stephan Schultz, Compress pathway senior Vice President of Investor relations. Please go ahead.

------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.